As per reports, the U.S. Food and Drug Administration has approved the cancer drug, jointly developed by Merck & Co., Inc. (MRK) and AstraZeneca Plc. (AZN) as a treatment for patients with early-stage breast cancer with certain mutations. The drug, Lynparza, was approved for patients suffering from BRCA-mutated HER2-negative, a form of genetically mutated high-risk early-stage breast cancer and who have already been treated before or after the surgery with chemotherapy.
The drug displayed statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences and second cancers or even death by 42% compared with placebo in a late-stage study. Following the U.S. approval for Lynparza, AstraZeneca will receive a regulatory milestone payment of $175 million from Merck.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.